Short answer: no SARM has been tested for joint healing or joint pain in people. The idea that ostarine or LGD-4033 “heal joints” comes from user reports, not studies. The closest evidence points the other way in places: a systematic review of SARM safety found a case of Achilles tendon rupture (Vignali 2023), and MK-677, often suggested for joints, caused more muscle pain than placebo and made two trial participants stop because of joint pain (FDA briefing on ibutamoren, 2024).
Below: the usual causes of joint pain in people who train or use these compounds, what each compound has actually shown, and what that means in practice. Persistent joint pain deserves a proper medical diagnosis.
Reasons For Joint Pain
The two reasons people in this area most often give:
- Load. Joints and tendons adapt more slowly than muscle, so fast strength gains during a cycle can outpace them. This is a common explanation; we found no study measuring it with SARMs. One case of Achilles tendon rupture appears among the SARM case reports collected in a 2023 systematic review (Vignali 2023).
- Very low estrogen. Joint pain is a known effect of low estrogen: in breast cancer trials of the aromatase inhibitor anastrozole, joint pain and arthritis were among the common side effects (anastrozole label). In men, the same can happen when an aromatase inhibitor is used to push estrogen down; see anastrozole for men.
Best SARMs For Joint Pain
There is no SARM with evidence for joint pain. What has been measured for the two usually mentioned:
| Compound | Joint or tendon data | What trials did show |
|---|---|---|
| Ostarine | None | About +1.3 kg lean mass over 86 days at 3 mg/day; lower HDL and total testosterone (Dalton 2011) |
| LGD-4033 | None | +1.21 kg lean mass in 21 days at 1 mg/day; testosterone, SHBG and HDL down with dose (Basaria 2013) |
The old version of this page recommended 10 mg of ostarine a day for six to eight weeks to “get rid of joint pain”. We removed it: no study supports it, 10 mg is more than three times the highest dose in the 86-day trial, and both SARMs lower testosterone. Users do report less joint discomfort on these compounds (anecdotal), but that can also reflect water retention or simply feeling better, which is different from healing. More: ostarine fact sheet, LGD-4033 fact sheet.
Alternatives to Ostarine
Three compounds often suggested instead, and what is known:
- MK-677 (ibutamoren): not a SARM. In a 12-month trial in older adults, short-lived muscle pain occurred in 14 of 43 on MK-677 vs 2 of 22 on placebo, and two people stopped because of joint pain; it also caused swelling and higher blood sugar (FDA briefing, 2024). There is no evidence it heals joints, and the old claim that a year of use is well tolerated has been removed. See the MK-677 fact sheet.
- BPC-157: faster healing of cut Achilles tendons in rats (animal study); in people, only small uncontrolled reports, such as a case series in which 14 of 16 patients with knee pain reported relief (case series). See the BPC-157 review.
- TB-500: never studied in people; the FDA found no human data (FDA briefing). See the TB-500 review.
Conclusion
SARMs are not a joint treatment: none has been tested for it, and the SARM safety literature includes a tendon rupture. MK-677 has the opposite problem in trials, with more muscle and joint pain than placebo. The peptide most often discussed, BPC-157, has encouraging animal data but only small uncontrolled human reports. If your joints hurt while training, load management and a diagnosis come first; compare the compounds’ evidence in the SARMs database before adding anything.
Frequently asked questions
What is the best SARM for joint health?
None has evidenceEvidence: Limited
No SARM has been tested for joint pain or healing in people. Ostarine and LGD-4033 are often suggested, but their trials measured lean mass and hormones, not joints.
Does ostarine help joint pain?
Not shownEvidence: Limited
Users report less joint discomfort, but ostarine's trials only measured lean mass, function and blood markers, and it lowered HDL cholesterol and testosterone.
Can SARMs cause joint or tendon problems?
Possibly; a tendon rupture is reportedEvidence: Human data
A 2023 systematic review of SARM safety in healthy adults included a case of Achilles tendon rupture. Very fast strength gains and low estrogen are commonly suggested reasons for joint pain, though neither has been studied with SARMs.
Is MK-677 good for joints?
Not according to the trialsEvidence: Trial
In a 12-month study, MK-677 caused short-lived muscle pain in 14 of 43 people vs 2 of 22 on placebo, and two stopped because of joint pain.
Does BPC-157 help joints?
Unproven in peopleEvidence: Animal
It sped up Achilles tendon healing in rats; in people there are only small uncontrolled reports, such as 14 of 16 patients with knee pain reporting relief in one case series. It is not approved anywhere.
Can low estrogen cause joint pain?
YesEvidence: Trial
Joint pain and arthritis are common side effects of aromatase inhibitors such as anastrozole in breast cancer trials. Pushing estrogen too low with an aromatase inhibitor can do the same in men.
Sources
- Systematic Review of Safety of Selective Androgen Receptor Modulators in Healthy Adults: Implications for Recreational Users
- FDA Briefing Document, Pharmacy Compounding Advisory Committee, 29 October 2024: Ibutamoren Mesylate
- ARIMIDEX (anastrozole) tablets – prescribing information (DailyMed, ANI)
- The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial
- The safety, pharmacokinetics, and effects of LGD-4033, a novel nonsteroidal oral, selective androgen receptor modulator, in healthy young men
- Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth
- Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain
- FDA Briefing Document, Pharmacy Compounding Advisory Committee, 23-24 July 2026: TB-500-related bulk drug substances